Dysfunctional uterine bleeding future or investigational therapies
|
Dysfunctional uterine bleeding Microchapters |
|
Differentiating Dysfunctional uterine bleeding from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Dysfunctional uterine bleeding future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Dysfunctional uterine bleeding future or investigational therapies |
|
FDA on Dysfunctional uterine bleeding future or investigational therapies |
|
CDC on Dysfunctional uterine bleeding future or investigational therapies |
|
Dysfunctional uterine bleeding future or investigational therapies in the news |
|
Blogs on Dysfunctional uterine bleeding future or investigational therapies |
|
Directions to Hospitals Treating Dysfunctional uterine bleeding |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Arooj Naz, M.B.B.S
Overview
Abnormal uterine bleeding has been found to affect a multitude of women, ranging from menarche to menopause. It can often result in conditions that affect an individual's daily routine and personal life, such as anemia and infertility. Because of such complications, it is important to continue researching and studying the causes of abnormal bleeding and providing further knowledge.[1] Due to the prevalence and high cost associated with surgical treatment of underlying causes, treatment must be tailored to the individual woman. Biomarkers continue to be studied and may provide crucial information.[2] Future studied regarding progesterone antagonists and progesterone receptor modulators are also being studied and may prove helpful in future therapy.[3]
Future or Investigational Therapies
Biomarkers
A biomarker[2] is an indicator that may be measured and used as an indicator for treatment response. Biomarkers have been studied for underlying conditions leading to abnormal bleeding.
| Cause of Abnormal Bleeding | Associated Biomarkers |
|---|---|
| Polyps |
|
| Adenomyosis |
|
| Leiomyoma/ Fibroids |
|
| Coagulopathy[4] | |
| Ovulatory disorders |
|
| Endometrial disorders |
|
Elastography
Elastography, a type of medical imaging done using MRI and ultrasonography, is used as a noninvasive biomarker for fibroids and adenomyosis. This method of diagnosis shows promise in allowing for individualized care and treatment response.[5]
References
- ↑ Levy-Zauberman Y, Pourcelot AG, Capmas P, Fernandez H (2017). "Update on the management of abnormal uterine bleeding". J Gynecol Obstet Hum Reprod. 46 (8): 613–622. doi:10.1016/j.jogoh.2017.07.005. PMID 28716637.
- ↑ 2.0 2.1 Chodankar R, Critchley HOD (2019). "Biomarkers in abnormal uterine bleeding†". Biol Reprod. 101 (6): 1155–1166. doi:10.1093/biolre/ioy231. PMC 6931000 Check
|pmc=value (help). PMID 30388215. - ↑ Samuel NC, Clark TJ (2007). "Future research into abnormal uterine bleeding". Best Pract Res Clin Obstet Gynaecol. 21 (6): 1023–40. doi:10.1016/j.bpobgyn.2007.03.018. PMID 17584533.
- ↑ Munro MG, Critchley HOD, Fraser IS, FIGO Menstrual Disorders Committee (2019). "Corrigendum to "The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions" [Int J Gynecol Obstet 143(2018) 393-408.]". Int J Gynaecol Obstet. 144 (2): 237. doi:10.1002/ijgo.12709. PMID 30609040.
- ↑ Jondal DE, Wang J, Chen J, Gorny KR, Felmlee J, Hesly G; et al. (2018). "Uterine fibroids: correlations between MRI appearance and stiffness via magnetic resonance elastography". Abdom Radiol (NY). 43 (6): 1456–1463. doi:10.1007/s00261-017-1314-1. PMC 6731767 Check
|pmc=value (help). PMID 28952003.